TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT1A and 5-HT1D receptor agonist, and 5-HT2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder. It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.
Attributes | Values |
---|---|
rdf:type | |
rdfs:label |
|
rdfs:comment |
|
dcterms:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage |
|
sameAs | |
dbp:wikiPageUsesTemplate | |
bioavailability |
|
elimination half-life |
|
routes of administration | |
SMILES |
|
StdInChI |
|
StdInChIKey |
|
synonyms |
|
has abstract |
|
Bioavailability |
|
gold:hypernym | |
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
foaf:isPrimaryTopicOf | |
is Link from a Wikipage to another Wikipage of | |
is Wikipage redirect of | |
is foaf:primaryTopic of |